

ESMO 2018 Industry Satellite Symposium

PARP Inhibition in Ovarian Cancer: Is It Time for a Paradigm Shift?

Monday, 22 October 2018

18:30-20:00

Hall B3-Room 20

Messe Munich

Munich, Germany

18:30-18:35

Welcome and Introductions

Susana Banerjee, MBBS, MA, PhD, FRCP – Chair

18:35-18:50

Pivotal Trials in Ovarian Cancer: What Has Defined the Standard of Care to Date?

Susana Banerjee, MBBS, MA, PhD, FRCP – Chair

18:50-19:20

Evaluating the Clinical Data for PARP Inhibitors in Platinum-Sensitive Relapsed Ovarian Cancer

Domenica Lorusso, MD, PhD

19:20-19:40

New Opportunities for Treating Ovarian Cancer

Kathleen N. Moore, MD, MS

19:40-20:00

Expert Panel Discussion and Audience Q&A

AstraZeneca 

 MSD

This meeting is organised and funded by AstraZeneca